Financial Performance - The total revenue for the year ended December 31, 2023, was HKD 1,572,305,000, representing an increase of approximately 9.35% compared to HKD 1,437,863,000 for the year ended December 31, 2022[9]. - The company reported a profit attributable to owners of HKD 11,295,000, a significant recovery from a loss of HKD 123,574,000 in the previous year[9]. - The basic earnings per share for the year was HKD 0.0122, compared to a basic loss per share of HKD 0.1694 in the previous year[9]. - The healthcare segment recorded revenue growth to HKD 1,521,859,000, up from HKD 1,382,134,000 in the previous year, with profit rising to HKD 85,839,000 from HKD 12,828,000[15]. - The EBITDA for the healthcare segment was HKD 202,095,000, compared to HKD 143,774,000 in the previous year[15]. - The revenue of the elderly care segment decreased to HKD 41,716,000 for the year ended December 31, 2023, down from HKD 49,787,000 in 2022, with a loss of HKD 46,684,000 compared to HKD 51,169,000 in the previous year[28]. - The property development segment's revenue fell to HKD 125,000 in 2023 from HKD 732,000 in 2022, with a loss reduced to HKD 2,065,000 from HKD 24,329,000[33]. - Rental income from investment properties was HKD 5,124,000 in 2023, slightly down from HKD 5,188,000 in 2022, with a profit of HKD 4,481,000 compared to a loss of HKD 9,397,000 in the previous year[34]. - The securities trading and investment segment recorded revenue of HKD 3,481,000 in 2023, down from HKD 22,000 in 2022, with a loss of HKD 2,009,000 compared to HKD 2,594,000 in the previous year[36]. Dividends and Shareholder Value - The company proposed a final dividend of HKD 0.01 per share, totaling approximately HKD 10,860,055, compared to no dividend in the previous year[11]. - The net asset value per share attributable to shareholders was HKD 1.72, down from HKD 2.15 in the previous year[10]. - The company proposed a share consolidation, merging every 20 existing shares into 1 new share with a par value of HKD 0.01, effective February 24, 2023[50]. - The company raised approximately HKD 318.6 million through a rights issue, issuing 362,001,819 shares at a subscription price of HKD 0.88 per share, with net proceeds of about HKD 309.3 million after expenses[52]. Healthcare Services Expansion - The company plans to continue expanding its healthcare services in response to the recovering demand post-pandemic[15]. - The company is focused on enhancing its investment and management capabilities in the healthcare sector, including potential new technologies and market expansion strategies[14]. - Nanjing Hospital established an allergy disease specialty clinic, improving its comprehensive treatment services[19]. - Nanjing Hospital completed the online payment system for medical insurance, significantly reducing patient wait times[19]. - Kunming Hospital plans to expand its key departments, including pathology and oncology, with a physical space adjustment of no less than 300 square meters and the recruitment of 5 staff members for pathology[70]. - The outpatient department will develop specialized services in ophthalmology, ENT, and dental care, focusing on high-value customer segments and personalized care[76]. - The group aims to strengthen its existing comprehensive medical services and traditional specialty areas such as ENT, ophthalmology, cardiology, and gynecology while diversifying into the health sector to enhance its competitive advantage[79]. Operational Efficiency and Cost Control - The company has implemented cost control measures, including optimizing the structure and pricing of medical supplies to reduce costs[30]. - The group will continue to maintain a cautious approach, focusing on improving operational efficiency, controlling costs, and strengthening its medical and technical teams amid a challenging economic environment[82]. - The group aims to create a high-quality, high-margin service system to effectively supplement basic medical services through the development of commercial insurance business and high-end customer membership operations[80]. Staffing and Human Resources - The company employed 2,599 staff as of December 31, 2023, an increase from 2,577 in the previous year[61]. - The elderly care business faced operational challenges, with a 30% average reduction in staff post-pandemic, leading to intensified competition[30]. - The nursing division plans to strengthen marketing efforts and establish referral partnerships with local hospitals and nursing homes to increase occupancy rates[78]. Governance and Corporate Structure - The board consists of ten members, including three executive directors, three non-executive directors, and four independent non-executive directors[161]. - The company has established six committees, including the Executive Committee and the Investment Committee, to assist in governance and oversight[179]. - The company has adopted a compensation policy for employees based on merit, qualifications, and capabilities, with the remuneration committee determining the pay for directors and senior management[146]. - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange rules, ensuring high standards of corporate governance[158]. - The company has established a whistleblower policy to allow employees and stakeholders to report concerns anonymously regarding potential misconduct[199]. Shareholder Information - As of December 31, 2023, Mr. Li Chenghui holds 556,022,010 shares, representing 51.19% of the total issued shares of the company[129]. - The major shareholders include Mr. Li Chenghui, Ms. Li Shuhui, and Mr. Li Chenghuang, each holding 556,022,010 shares, equating to 51.19%[138]. - The company has a total of 1,086,005,457 shares issued as of December 31, 2023, with major shareholders holding approximately 8.98% each[140]. Future Outlook and Strategic Initiatives - The group is advancing the second phase of the Kunming Hospital project, focusing on the development of oncology and nuclear medicine disciplines as a strategic initiative[82]. - The group intends to establish an international department within hospitals to collaborate on high-end medical services, enhancing its service offerings[80]. - The group will review and adjust its business and investment policies to adapt to the challenging economic and investment environment in China, Hong Kong, and the Asia-Pacific region[82].
中国医疗网络(00383) - 2023 - 年度财报